Literature DB >> 17615466

[Comparison of the metabolic syndrome risk factor prevalence forty and fifty something women].

Hee Seung Kim1, Jeong Ah Oh.   

Abstract

PURPOSE: The purpose of this study was to compare metabolic syndrome (MS) risk factor prevalence by obesity and age in middle-aged women.
METHOD: Two hundred and fifty-one subjects were recruited from the health promotion center of a tertiary care hospital in an urban city. MS was defined by the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III)(ATPIII), and obesity was determined by body mass index(BMI)>/= 25kg/m(2).
RESULTS: The mean blood pressure, fasting glucose, total cholesterol, and triglyceride were significantly higher in the obese group than in the non-obese group. The prevalence of MS, hypertension, and impaired fasting glucose were significantly higher in the obese group than in the non-obese group. In the forties, blood pressure was significantly higher in the obese group than in the non-obese group. In the fifties, body fat, systolic blood pressure, fasting glucose, total cholesterol, and triglyceride were significantly higher in the obese group than in the non-obese group.
CONCLUSIONS: These results show that the nurse should focus on the obese fifty year old female patients for improvement of the MS risk factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17615466     DOI: 10.4040/jkan.2007.37.4.453

Source DB:  PubMed          Journal:  Taehan Kanho Hakhoe Chi        ISSN: 1598-2874


  2 in total

1.  Relation of serum total antioxidant status with metabolic risk factors in Korean adults.

Authors:  Ho-Kyung Kwak; Sun Yoon
Journal:  Nutr Res Pract       Date:  2007-12-31       Impact factor: 1.926

2.  The effect of salt usage behavior on sodium intake and excretion among Korean women.

Authors:  Jeung Yun Lee; Dong Sook Cho; Hyun Ju Kim
Journal:  Nutr Res Pract       Date:  2012-06-30       Impact factor: 1.926

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.